Fig. 5

PSMA3-AS1 contains a miR-329-3p binding site. (A) The potential binding site for miR-329-3p in PSMA3-AS1 (site 1) was predicted by bioinformatics analysis. (B) Total RNAs were isolated from fresh clinical specimens. MiR-329-3p levels in 20 paired clinical specimens were examined by real-time PCR (n = 20). U6 served as an internal control. (C) The cells were co-transfected with miR-329-3p mimic or NC mimic and wild-type or mutant PSMA3-AS1 (site 1). The binding of miR-329-3p to PSMA3-AS1 was verified by a dual-luciferase reporter assay (n = 3). (D) MiR-329-3p levels in stable transfectants were examined by real-time PCR (n = 3). U6 served as an internal control. (E) The copy numbers of miR-329-3p in stable transfectants were determined by ddPCR. Results are expressed as copies/µl (n = 3). ^**P < 0.01 compared with Normal, sh-NC, vector, or NC mimic. Student′s t-test was used to compare two groups, and one-way ANOVA with Tukey′s post-hoc test was used to compare multiple groups